News
Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...
Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...
The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...
3d
Pharmaceutical Technology on MSNModerna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump
"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...
4d
Stocktwits on MSNModerna CEO Attributes Full-Year Revenue Guidance Reduction To Timing Of Shipments: Retail Pins Hopes On Pipeline After Q2 Beat
CEO Stéphane Bancel on Friday stated that the company is lowering its annual revenue forecast due to the timing of shipments ...
It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...
In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results